Navigation Links
Biological markers of prostate cancer shed light on cancer burden faced by African-American men
Date:11/29/2007

ATLANTA -- Researchers based at Tulane University report the discovery of biological markers of prostate cancer which are involved in the growth of tumor cells, shedding light on the genetic basis for the prostate cancer burden faced by African-American men. The research is being presented today at the American Association for Cancer Research conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, being held November 27-30.

In prostate tumors samples taken from African-American and Caucasian men, the researchers found that two proteins are overproduced in 90 percent of tumor cells from the African-Americans studied. These structural proteins, called hnRNP-H1 and SAFB-2, in part comprise the nuclear matrix, the mesh of molecules that serves as the supporting skeleton of the cells nucleus.

We have employed a unique functional genomics approach to unravel the molecular mechanisms underlying the disproportionate incidence and mortality among African-American men, said Asim B. Abdel-Mageed, D.V.M, Ph.D., associate professor and director of the Molecular Oncology Research program in the Department of Urology at Tulane University School of Medicine.

Currently, prostate specific antigen (PSA) and digital rectal examinations are the two most common methods of detecting prostate cancer. African Americans are typically diagnosed with prostate cancer more frequently and later when the cancer is at an advanced stage and more aggressive than any other ethnic group in the United States. According to Abdel-Mageed, earlier detection of prostate cancer might decrease this health disparity. The target genes may have potential clinical utility as biomarkers or prognostic indicators of disease progression in African-American men independent of a PSA screen, Abdel-Mageed said.

With funding from the National Cancer Institute and American Cancer Society, the researchers compared prostate cancer cells from 50 African-American and Caucasian men, aged 50 to 60, matched so that each group comprised similar tumor grades. Using DNA sequencing and screening techniques to determine the genetic activity of these tumor cells, the researchers demonstrated the increased production of heterogeneous nuclear ribonucleoprotein H1 (hnRNP-H1) and scaffold attachment factor B2 (SAFB-2) in African-American men as opposed to Caucasians.

In addition to their role as potential blood-borne biomarkers for disease screening, the researchers are excited by the role these proteins play in chemical pathways that control disease progression. Both of these genes share many structural and functional similarities, including possession of messenger RNA binding sites that could allow them to regulate how other genes are read from the DNA, said Abdel-Mageed.

Through related means, Abdel-Mageed says, these proteins are somehow involved in the relationship between hormones and prostate cancer progression. The researchers determined that hnRNP-H1 protein, in particular, binds to and activates the androgen receptor (AR), a nuclear protein that serves as an intermediate that allows male hormones from the bloodstream, such as testosterone, to activate genes encoded in the DNA. Testosterone and other hormones have been shown to influence prostate cancer growth, Abdel-Mageed says.

Similarly, SAFB-2 was shown to have a role in regulation of hormone-related genes. Based on these data, we believe their selective expression may represent a novel a mechanism for disease progression and development of hormone refractory disease in African Americans, said Abdel-Mageed.


'/>"/>

Contact: Greg Lester
greg.lester@aacr.org
267-646-0554
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Thomson Scientific Announces BONDplus for Biological Researchers
2. Neurobiological Technologies Reports Going Concern Qualification
3. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
4. Study questions assumptions about human sensitivity to biological motion
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
7. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
8. UCLA researchers identify markers that may predict diabetes in still-healthy people
9. Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure
10. Study makes progress in zoning in on biomarkers for better colon cancer treatment
11. Study shows blood markers can help choose best dose for antiangiogenic drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Caronlab Australia, an Australian company ... ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding meetings with ... of its beauty and wellness products. At this trade show, the company had the ...
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... Director of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its ... for alumni, family, friends, and community. “Coming Home 2017” will be held ...
(Date:1/20/2017)... ... 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. Built for ... mounted on wheels, it can be wheeled out of the way and stored when not ... deck. "We have transformed the feedback from customers into specific enhancements and created a new ...
(Date:1/20/2017)... ... 2017 , ... Bionic Sports Nutrition LLC, an American company devoted to developing ... successful January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition ... provide its products to all clients at reasonable prices. At the ECRM trade show, ...
(Date:1/20/2017)... ... ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that are fully ... - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains 44 lens ... and light leak transitions have a very high-dynamic range for super smooth falloff. Simply ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017  Faruqi & Faruqi, LLP, ... Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH ) ... Company and certain officers and directors and underwriters of the ... seek the role of lead plaintiff. The lawsuit ... District Court for Johnson County on ...
(Date:1/20/2017)... Research and Markets has announced the addition of ... OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company Analysis and Forecast ... ... Sales Volume, Company Analysis and Forecast to 2022 provides a ... The growing prevalence of hearing impairment coupled with an ...
(Date:1/20/2017)... -- Stock-Callers.com today evaluates the following Drug Manufacturers ... Nordisk A/S (NYSE: NVO ), Sucampo Pharmaceuticals Inc. ... (NASDAQ: PTX ). These stocks belong to the ... 2017, finishing near its session lows. As per a NASDAQ ... shares of health care companies in the S&P 500 also ...
Breaking Medicine Technology: